Calcium Carbonate on Labor Induction
The Effect of Calcium Carbonate on Labor Induction: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jessica Kram, MPH
- Phone Number: 414-219-5594
- Email: jessica.kram@aah.org
Study Contact Backup
- Name: Emily Malloy, PhD, CNM
- Phone Number: 414-219-6649
- Email: emily.malloy@aah.org
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53233
- Aurora Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult laboring patients ( ≥ 18 years of age)
- Able to speak and read English or Spanish (for historical cohort, preferred language should be English or Spanish)
- Singleton gestation
- Greater ≥ 37 weeks gestation in vertex presentation
- Present for induction of labor inclusive of medical indication, elective indication at greater than 39 weeks gestation, trial of labor after cesarean
- Receive standard-dose oxytocin during induction
Exclusion Criteria:
- Participants will be excluded from the study if they do not meet the above inclusion criteria or they will be further excluded under the following circumstances:
- Known need for cesarean section prior to induction of labor
- Known allergy to calcium carbonate
- Known contraindication to taking calcium carbonate including renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity.
- Inability to tolerate oral intake (i.e., nausea/vomiting)
- Need to be nothing by mouth (NPO)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Prospective Treatment Group
Patients receive calcium carbonate (500mg every 4 hours, per standardized treatment protocol) plus standard-dose oxytocin for labor induction
|
We will be using it in routes and doses consistent with its approved uses.
Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours.
Therefore, using a dosing of 500mg every 4 hours will be well below that guidance.
When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
|
|
No Intervention: Retrospective Historical Control Group
Patients who presented for induction at the same institution within the previous three years and received standard-dose oxytocin alone for labor induction and were not treated with calcium carbonate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of induction time
Time Frame: During the intervention (time from duration of induction with oxytocin start to delivery)
|
Participants in the treatment group will have a shorter duration of induction with oxytocin than those in the retrospective historical control group.
|
During the intervention (time from duration of induction with oxytocin start to delivery)
|
|
Rate of labor dystocia
Time Frame: During the intervention (measured from time of induction to delivery)
|
Participants in the treatment group will have a lower rate of labor dystocia than those in the retrospective historical control group.
|
During the intervention (measured from time of induction to delivery)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of cesarean deliveries
Time Frame: During the intervention (measured from time of induction to delivery)
|
Participants in the treatment group will have a lower rate of cesarean deliveries than those in the retrospective historical control group.
|
During the intervention (measured from time of induction to delivery)
|
|
Total amount of oxytocin after cervical ripening
Time Frame: During the intervention (time on oxytocin after cervical ripening completed to delivery)
|
Participants in the treatment group will receive a lower amount of oxytocin than those in the retrospective historical control group.
|
During the intervention (time on oxytocin after cervical ripening completed to delivery)
|
|
Gastrointestinal side effects
Time Frame: During the intervention (time on calcium carbonate to delivery)
|
Participants in the treatment group will describe gastrointestinal side effects.
|
During the intervention (time on calcium carbonate to delivery)
|
|
Blood loss
Time Frame: Time from delivery to 24 hours of birth
|
Participants in the treatment group will experience less blood loss than those in the retrospective historical control group.
|
Time from delivery to 24 hours of birth
|
|
Rate of postpartum hemorrhage (>/= 500mL)
Time Frame: Time from delivery to 24 hours of birth
|
Participants in the treatment group will experience less postpartum hemorrhage than those in the retrospective historical control group.
|
Time from delivery to 24 hours of birth
|
|
Neonatal composite adverse outcomes
Time Frame: Immediately after the birth until the time of discharge, an average of 3 days
|
Neonates of participants in the treatment group will have comparable composite adverse outcomes to those born to participants in the retrospective historical control group.
|
Immediately after the birth until the time of discharge, an average of 3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marie Forgie, DO, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00107112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.